Abstract
Currently, patients with cancer are undoubtedly more likely to develop thrombosis and thromboembolism. In some cases, symptoms of thrombotic complications could be the first signs of a malignant tumor. Thus, the treatment of such patients should follow two directions: treatment of cancer and maintenance therapy aimed at coagulopathy correction. Anticoagulant and antiplatelet therapies are high priorities in the treatment of these conditions; however, their adverse effects should not be forgottenhigh risk of bleeding. There is a very fine line between the risks of thromboembolic complications and bleeding; both conditions can threaten the patients life. Thus, a multidisciplinary approach, timing, and balanced treatment can save patients lives.